HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Tong Ren Tang Technologies (1666.HK) - Undervalued; Performance Will Rebound After a Brief Headwind

Pre-IPO China Resources Beverage (PHIP Updates) - Some Points Worth the Attention

Pre-IPO China Resources Beverage - Due to the Pain Points, High Valuation Is Not Justified

Pre-IPO Midea Group H Share - Here Are the Risks Behind

Pre-IPO LinkChem Technology - The Business and the Concerns Behind

Pre-IPO Zhejiang Taimei Medical Technology - Be Cautious About the “valuation Bubble”

Equity Capital Markets

Zhejiang Taimei Medical Technology Co Ltd / Equity Capital Markets

Zhejiang Taimei Medical Technology Co Ltd (1482194D CH)

Zhejiang Taimei Medical Technology Co Ltd

<ul>
<li>Declining customer retention rate indicates that a slowdown in future revenue growth seems inevitable. If revenue growth stagnates, it means Taimei’s business model hasn’t been fully validated by the market.</li>
<li>Taimei’s IPO on SSE STAR Market was rejected. This means regulatory authorities don’t recognize Taimei's core technology/performance prospects. Taimei has to take a step back and list on the HKEX.</li>
<li>Post-Investment valuation reached RMB8.1 billion after Series F financing. However, considering the continuous decline in valuation of its peers, we are concerned about Taimei's future stock price performance after IPO.</li>
</ul>


Declining customer retention rate indicates that a slowdown in future revenue growth seems inevitable. If revenue growth stagnates, it means Taimei’s business model hasn’t been fully validated by the market.
Taimei’s IPO on SSE STAR Market was rejected. This means regulatory authorities don’t recognize Taimei's core technology/performance prospects. Taimei has to take a step back and list on the HKEX.
Post-Investment valuation reached RMB8.1 billion after Series F financing. However, considering the continuous decline in valuation of its peers, we are concerned about Taimei's future stock price performance after IPO.


Pre-IPO Zhejiang Taimei Medical Technology (PHIP Updates) - Some Points Worth the Attention